Alamar Biosciences Launches NULISAqpcr BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next…
Enovix Korea Named 2025 Best Workplace for Job Creation in Korea by Ministry of Employment and Labor
FREMONT, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX)…
ACM Research Delivered Its First High-Throughput Ultra Lith KrF Track System to a Leading Chinese Logic Wafer Fab Customer
September 07, 2025 20:00 ET Â | Source: ACM Research, Inc. New Ultra…
Enovix Shareholder Second Reminder: Early Warrant Expiration Price Condition
Enovix Warrants: 14 of 14 Trading Days Above $10.50 August 08, 2025…
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseqâ„¢ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker…
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters…
ACM Research to Participate at the 15th Annual ROTH London Conference
June 13, 2025 16:05 ET Â | Source: ACM Research, Inc. FREMONT, Calif.,…
Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISAâ„¢ technology. FREMONT,…